Received Mar 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 2 | — | — |
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 1 | — | — |
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 3 | — | — |
No additional AE; Customer called and reported that an additional dose of MMR-II was administered to a 5-year-old consumer after the series was completed. The final dose of the series was administered on 2/15/2024. The additional dose was administered on 2/13/2025; This spontaneous report was received from a nurse and refers to a 5-year-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On an unknown date, the patient was vaccinated with the first dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) (strength, dose, lot #, and expiration date were not reported) for prophylaxis, diluted in sterile diluent (MERCK STERILE DILUENT), (indication, expiration date, and lot # were not reported). On 15-Feb-2024, the patient received the final dose of the series of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), dose number 2, (lot # and expiration date were not reported), diluted in sterile diluent (MERCK STERILE DILUENT), (indication, expiration date, and lot # were not reported). On 13-Feb-2025 (after the series were completed), the patient received a third dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II),, dose number 3, (lot # and expiration date were not reported) diluted in sterile diluent (MERCK STERILE DILUENT), (indication, expiration date, and lot # were not reported) (Extra dose administered). No additional adverse event was reported.
STERILE DILUENT